SAN FRANCISCO — With a new deal to use CRISPR to hunt for new drugs, the drug maker GlaxoSmithKline and the leading academic gene-editing researchers it’s collaborating with are embarking on a first-of-its-kind partnership.

But the collaboration raises questions that are familiar to many partnerships between academic and industry researchers: What will each party get out of the deal? What will get published? And will GSK exert undue influence on what gets studied?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy